Overview
Collagen is the most common structural protein in the skin and connective tissues of the body. About 29 different types have been identified, with 90% being type I and type II collagen. Type I collagen is found in tendons, ligaments, fascia, skin, bones, organs, heart valves, and blood vessels. Type II collagen is present in 70% of the body’s cartilaginous tissue, including hyaline and articular cartilage, as well as intervertebral discs. Over time, factors such as age, lifestyle, genetics, past injuries, inflammation, and biomechanical instability can cause collagen breakdown and slow healthy collagen production.
Collagen Hydrolysate
FORTIGEL®, supported by over 15 studies, offers highly concentrated bioactive collagen peptides (BCPs) that have been shown to stimulate chondrocytes to produce proteoglycans and type II collagen. This collagen has been hydrolyzed into short-chain peptides with low molecular weight, making it easier to absorb, transport, and accumulate in target connective tissues. FORTIGEL® provides 5 g of hypoallergenic protein per serving from a sustainable protein source. This lower dose reduces excess oxalate production compared to higher-dose collagen and gelatin products.
Numerous clinical studies have demonstrated the effectiveness of FORTIGEL®. A randomized, double-blind, placebo-controlled trial conducted in collaboration with Harvard Medical School and Tufts Medical Center confirmed FORTIGEL®’s ability to promote cartilage production. Thirty participants took collagen hydrolysate daily for 48 weeks. Using delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMERIC), researchers assessed hyaline cartilage and proteoglycan content in the knee joints at baseline, 24 weeks, and 48 weeks. The group taking FORTIGEL? showed significant improvements in primary dGEMERIC scores, indicating a potential to stimulate chondrocytes and maintain cartilage tissue. At Penn State University, 147 athletes used FORTIGEL? for 24 weeks. The results supported the role of FORTIGEL® in maintaining normal joint mobility and health. A 2021 clinical study involving 180 young adults who took 5 g of BCPs over 12 weeks found a significant reduction in exercise-induced joint pain. Lastly, a trial involving 160 subjects found that 5 g was an effective dose for supporting joint health.
